TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Nov 02, 2022 10:43 JST
Source:
Eisai
Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination
TOKYO, Nov 02, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received notification that Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies that was discovered and developed in-house, has been granted Category 2* status based on the results of a reexamination of its efficacy, dosage and administration for the treatment of dementia with Lewy bodies (DLB) in Japan. In conjunction with this, Eisai plans to promptly submit an application for a partial change to label regarding dosage and administration. The indication for DLB remains unchanged.
The indication of "suppression of progression of dementia symptoms in DLB" was approved in September 2014, primarily based on a Phase II study (Study 431) and Phase III study (Study 341) conducted by Eisai on people living with DLB in Japan. In accordance with the condition for the approval of this indication, "a clinical trial to verify the efficacy and safety of the drug in patients with DLB should be conducted and the results of the trials and analyses should be submitted promptly after completion," Eisai conducted a post-marketing clinical study (Study 419) to evaluate the efficacy and safety of the drug in patients with DLB.
The results of Study 419 did not show a statistically significant difference between the placebo group and the Aricept group in the primary endpoint of global function (CIBIC-plus** comprehensive assessment), but the re-examination based on post-marketing studies, including the results of Study 419, stated that "at present, the evaluation of clinical function in DLB using CIBIC-Plus is not always sufficiently established as an evaluation method, and it is difficult to comprehensively evaluate the efficacy of this drug for DLB, although efficacy was seen in some patients. On the other hand, treatment with this drug showed a trend toward improvement in cognitive function (MMSE***), and this result is consistent with the results of the clinical trial at the time of approval of the drug. Since there are a certain number of patients who can be expected to benefit from the administration of this drug, it was concluded that the efficacy should be evaluated after the start of administration, and administration should only continue if efficacy is confirmed."
Therefore, it was concluded that the approved label (dose and administration) and package insert should be appropriately revised (Category 2).
The condition of the approval was lifted as of the date of receipt of the reexamination results.
Along with this prompt application for a partial change to label regarding dosage and administration for the DLB indication, Eisai will place the highest priority on the provision of proper use and safety information for this drug, and will make continued contributions to address the diversified needs of, and increase the benefits provided to people living with DLB and their families.
For more information, visit www.eisai.com/news/2022/news202274.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
January 27 2023 10:46 JST
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
January 19 2023 09:35 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
January 19 2023 08:07 JST
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
January 18 2023 12:28 JST
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
January 16 2023 17:56 JST
Eisai Launches Renewed Sustainability Page
January 13 2023 14:06 JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
January 11 2023 11:52 JST
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09 2023 20:55 JST
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09 2023 19:40 JST
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22 2022 17:07 JST
More Press release >>
Latest Press Release
Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project
Jan 27, 2023 15:25 JST
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
Jan 27, 2023 11:46 JST
TMC Announces Changes to Executive Structure
Jan 27, 2023 10:59 JST
Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region
Jan 26, 2023 19:16 JST
Kurita Water Industries and Hitachi Launch a Co-creation to Implement Solution in Society and Build an Ecosystem for a Sustainable Society with "Zero Environmental Impact"
Jan 26, 2023 19:02 JST
Four Companies Announce Joint Feasibility Study of Large-Scale and Wide-Area Carbon Capture and Storage (CCS) Value Chain Project Using Ship Transportation
Jan 26, 2023 18:28 JST
Mitsubishi Power Receives Order for H-25 Gas Turbine for Taiwan's Chang Chun Petrochemical
Jan 26, 2023 18:22 JST
Fujitsu and Mizuho Bank embark on collaboration for sustainable management information services
Jan 26, 2023 13:44 JST
All-New eK X EV Earns Top Rating in Vehicle Safety Performance 2022 Car Assessment by JNCAP
Jan 26, 2023 09:01 JST
DOCOMO Announces World's First Technology that Utilizes Human-Augmentation Platform for Sharing Haptic Information Between People
Jan 25, 2023 17:17 JST
EEJA (TANAKA Precious Metals) to Exhibit at 37th INTERNEPCON JAPAN
Jan 25, 2023 11:00 JST
EEJA (TANAKA Precious Metals) to Exhibit at 37th INTERNEPCON JAPAN
Jan 25, 2023 11:00 JST
Hitachi Astemo, Trend Micro, and VicOne Expand Collaboration on Security Solutions for Connected Cars, Targeting 2025 Commercialization
Jan 25, 2023 09:02 JST
Honda to Make Organizational Changes (Effective April 1, 2023) to Further Accelerate Electrification Business and Realize New Value Creation
Jan 24, 2023 17:18 JST
Honda and GS Yuasa Reach Basic Agreement Toward Collaboration for a High-capacity, High-output Lithium-ion Battery
Jan 24, 2023 16:02 JST
KDDI starts commercial deployment of 5G Open vRAN sites in Japan in collaboration with Samsung Electronics and Fujitsu Limited
Jan 24, 2023 10:22 JST
Nurburgring gives green light for a comprehensive digitization measure of the world-famous Nordschleife
Jan 23, 2023 16:55 JST
NBB and JCB Enable the Acceptance of JCB Cards Through its POS & E-Commerce Merchants in The Kingdom of Bahrain
Jan 23, 2023 15:00 JST
JCB starts Red Guahan Shuttle Free Ride Campaign in Guam
Jan 23, 2023 12:00 JST
Ogier claims ninth Monte win in TOYOTA GAZOO Racing one-two
Jan 23, 2023 11:23 JST
More Latest Release >>